Dawson James analyst Jason Kolbert initiates coverage on Brainstorm Cell Therapeutics (NASDAQ: BCLI) with a Buy rating and a price ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot New Coverage New Coverage